Welcome to DailyUpdates Psychiatric, Addictive & Sleep Disorders channel - the R&D community's bulletin of breaking research, clinical trials and drug development news. This page will update each day. You have access for 2 more day(s). To receive DailyUpdates by e-mail register here


PubMed DailyUpdates: Breaking Scientific Publications for the Drug Discovery Community

DailyUpdates by e-mail - the publication tracker for the drug discovery community

Psychiatric, Addictive & Sleep Disorders channel



If this icon appears after any of our listed articles, the author is able to provide reprints. Articles denoted by an Licensing Op. icon describe data relevant to licensing opportunities. The report icon, , links through to full analyses relating to pharmaceutical/market developments relating to this work

Today's journal articles

Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics.

Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know...

New Clinical Trials

No clinical trials today

Previous Journal Entries

Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study.

Design, synthesis, and pharmacological effects of structurally simple ligands for MT(1) and MT(2) melatonin receptors.

Novel imidazobenzazepine derivatives as dual H(1)/5 - HT(2A) antagonists for the treatment of sleep disorders.

Ameliorating effects of tropisetron on dopaminergic disruption of prepulse inhibition via the alpha(7) nicotinic acetylcholine receptor in Wistar rats.

Structure - Activity Relationships for a Novel Series of Citalopram (1 - (3 - (Dimethylamino)propyl) - 1 - (4 - fluorophenyl) - 1,3 - dihydroisobenzofuran - 5 - carbonitrile) Analogues at Monoamine Transporters.

Efficacy and Tolerability of Blonanserin in the Patients With Schizophrenia: A Randomized, Double-blind, Risperidone-Compared Trial.

Neuropsychological rehabilitation in adult multiple sclerosis.

Comparison of Hippocampal Metabotropic Glutamate Receptor 7 (mGlu(7)) mRNA Levels in Two Animal Models of Depression.

Does short-wave diathermy increase the effectiveness of isokinetic exercise on pain, function, knee muscle strength, quality of life, and depression in the patients with knee osteoarthritis? A randomized controlled clinical study.

Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia.

Anxiolytic Effects of the MCH1R Antagonist TPI 1361-17.

The H(3) Antagonist, Ciproxifan, Alleviates the Memory Impairment but Enhances the Motor Effects of MK-801 (Dizocilpine) in Rats.

Intensification of long-term memory deficit by chronic stress and prevention by nicotine in a rat model of Alzheimer's disease.

Duloxetine for the Treatment of Generalized Social Anxiety Disorder: A Preliminary Randomized Trial of Increased Dose to Optimize Response.

Depression and Cognitive Impairment in Newly Diagnosed Systemic Lupus Erythematosus.

In vitro and in vivo characterization of a novel negative allosteric modulator of neuronal nAChRs.

Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: A randomized, double-blind, dose-response study.

A Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled, Dose-Optimization Study of the Methylphenidate Transdermal System for the Treatment of ADHD in Adolescents.

Synthesis and in vivo evaluation of [(11)C]tariquidar, a positron emission tomography radiotracer based on a third - generation P - glycoprotein inhibitor.

Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: A PET study with [(11)C]verapamil as a probe for P-glycoprotein function.

Today's News Items

No news items selected today

Training Courses & Meetings

No events listed

Previous News Items

Forest Laboratories, Inc. and Gedeon Richter Plc Announce Results from a Phase II Study of Cariprazine for the Treatment of Bipolar Depression